Shots:
- Eli Lilly reports additional data on its SARS-CoV-2 neutralizing Ab programs including interim data on combination therapy in diagnosed patients with mild-to-mod. COVID-19 and plans to make therapies available to patients
- The new analysis P-II BLAZE-1 study assessing LY-CoV555 (2800mg) + LY-CoV016 (2800mg) vs PBO demonstrated reduced viral load@11days. meeting its 1EPs, reduction in symptoms and COVID-related hospitalization and ER visits
- Based on the combination regimen data, along with the previous findings for LY-CoV555, Lilly has submitted the initial EUA for LY-CoV555 monothx. and plans to initiate a large open-label pragmatic study in COVID-19 outpatients in Oct’2020. Additionally, Lilly anticipates the data supporting BLA submission for dual regimen as early as Q2’21
Click here to read full press release/ article | Ref: Eli Lilly | Image: GMP News
The post Eli Lilly Seeks the US FDA’s EUA for its COVID-19 Antibody Treatment first appeared on PharmaShots.